{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/652558c78b631000124f5568/66476fffe1c79600121bec45?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Why is there a delay in HS patient diagnosis?","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/652558c78b631000124f5568/1715957547835-53ffc22c8b1ee81e8f2d2e320efa8c9e.jpeg?height=200","description":"<p>This podcast is aimed at healthcare professionals, produced and funded by UCB.&nbsp;</p><p>For our third episode, our host Dr Barry McGrath, PhD, is joined by Dr Philippe Guillem, hidradenitis suppurativa Surgeon from Lyon, France. On this episode, they explore the various barriers to, and the consequences of, an HS diagnosis, and discuss how we can work towards achieving an earlier diagnosis together.&nbsp;&nbsp;</p><p><br></p><p><strong>Speaker disclosures:</strong>&nbsp;</p><p>Dr Barry McGrath, and Dr Philippe Guillem have received consulting fees, research or institutional support and educational grants from UCB.&nbsp;</p><p>Dr Barry McGrath, PhD, has received consultancy/advisory board disease-related honoraria from Novartis and UCB.&nbsp;</p><p>Dr Philippe Guillem has received consultancy/advisory board disease-related honoraria from AbbVie, Novartis and UCB.&nbsp;</p>","author_name":"UCB Biopharma"}